艾伯维斥资100亿美元收购Immunogen！ADC药物开发商股价多数走高

智通财经网2023-12-01

艾伯维(ABBV.US)周四宣布，以约100亿美元收购新型抗癌疗法抗体偶联药物(ADC)开发商Immunogen(IMGN.US)。受此影响，Immunogen周四收涨近83%，艾伯维收涨近3%。其他开发ADC药物的生物科技公司股价同样走高：Sutro Biopharma(STRO.US)收涨约13%，Mersana Therapeutics(MRSN.US)收涨超3%，ADC ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2388472603?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","is_english":false,"pubTime":"2023-12-01 08:20","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2388472603","market":"us","top_or_hot":-1,"title":"艾伯维斥资100亿美元收购Immunogen！ADC药物开发商股价多数走高","media":"智通财经网","content":"<div>\n<p>艾伯维(ABBV.US)周四宣布，以约100亿美元收购新型抗癌疗法抗体偶联药物(ADC)开发商Immunogen(IMGN.US)。受此影响，Immunogen周四收涨近83%，艾伯维收涨近3%。其他开发ADC药物的生物科技公司股价同样走高：Sutro Biopharma(STRO.US)收涨约13%，Mersana Therapeutics(MRSN.US)收涨超3%，ADC ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1031965.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>艾伯维斥资100亿美元收购Immunogen！ADC药物开发商股价多数走高</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n艾伯维斥资100亿美元收购Immunogen！ADC药物开发商股价多数走高\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-01 08:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1031965.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>艾伯维(ABBV.US)周四宣布，以约100亿美元收购新型抗癌疗法抗体偶联药物(ADC)开发商Immunogen(IMGN.US)。受此影响，Immunogen周四收涨近83%，艾伯维收涨近3%。其他开发ADC药物的生物科技公司股价同样走高：Sutro Biopharma(STRO.US)收涨约13%，Mersana Therapeutics(MRSN.US)收涨超3%，ADC ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1031965.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0820561909.HKD","symbol_name":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1031965.html","article_id":"2388472603","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2388472603","pubTimestamp":1701390006,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"Immunogen周四收涨近83%，艾伯维收涨近3%。其他开发ADC药物的生物科技公司股价同样走高。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0882574055.USD":"富达全球健康医疗A ACC","BK4080":"零售业房地产投资信托","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4559":"巴菲特持仓","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","BK4231":"零售房地产信托","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4581":"高盛持仓","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","ABBV":"艾伯维公司","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","IMGN":"ImmunoGen","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"Albertville buys Immunogen for $10 billion! Most shares of ADC drug developers are higher","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/20f1ad2fe69ddec6daa53f54d7e7a7d0","symbols_score_info":{"ABBV":1.1,"IMGN":1},"content_text":"艾伯维(ABBV.US)周四宣布，以约100亿美元收购新型抗癌疗法抗体偶联药物(ADC)开发商Immunogen(IMGN.US)。受此影响，Immunogen周四收涨近83%，艾伯维收涨近3%。其他开发ADC药物的生物科技公司股价同样走高：Sutro Biopharma(STRO.US)收涨约13%，Mersana Therapeutics(MRSN.US)收涨超3%，ADC Therapeutics(ADCT.US)收涨约8%。此外，专注于中小型生物科技公司的SPDR标普生物技术ETF收涨2%，纳斯达克生物技术指数收涨超1%。根据交易条款，艾伯维将以每股31.26美元现金收购ImmunoGen，较后者周三收盘价溢价约95%。此次收购包括Immunogen旗下卵巢癌症疗法Elahere。艾伯维表示，这项交易预计将于2024年中期完成。从2027年初开始，这一收购将提高其摊薄后每股收益。艾伯维首席执行官Richard Gonzalez表示：“收购ImmunoGen表明了我们致力于实现长期增长战略的承诺，并使艾伯维能够在实体肿瘤和血液系统恶性肿瘤领域进一步实现产品管线的多元化。”Guggenheim分析师Michael Schmidt表示，这笔交易的价格反映出大型制药公司希望增加在ADC领域的投资的兴趣日益浓厚。他表示，ADC药物是“有吸引力的领域”。今年早些时候，辉瑞(PFE.US)宣布以430亿美元收购ADC开发商Seagen(SGEN.US)。10月，默沙东(MRK.US)同意向日本制药公司Daiichi Sankyo(DSKYF.US)支付高达220亿美元，共同开发和商业化三种针对实体肿瘤的ADC。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2388472603"}